spironolactone has been researched along with Cardiometabolic Syndrome in 25 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Cardiometabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aim of the study is to evaluate the impact of spironolactone (SPL) on indexes of metabolic syndrome (MS) and further investigate the mechanisms underlying its protective effects." | 7.79 | Spironolactone prevents dietary-induced metabolic syndrome by inhibiting PI3-K/Akt and p38MAPK signaling pathways. ( Liang, LY; Lin, YE; Liu, MJ; Long, HD; Zeng, ZH, 2013) |
| "Because the renin-angiotensin-aldosterone system has been implicated in the development of insulin resistance and promotion of fibrosis in some tissues, such as the vasculature, we examined the effect of eplerenone, a selective mineralocorticoid receptor (MR) antagonist, on nonalcoholic steatohepatitis (NASH) and metabolic phenotypes in a mouse model reflecting metabolic syndrome in humans." | 7.79 | Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet. ( Aruga, Y; Ishii, Y; Kanasaki, K; Kitada, M; Koya, D; Miyashita, Y; Nakamura, Y; Sasahara, M; Sasaki, M; Sasaoka, T; Shimano, H; Tsuneki, H; Wada, T, 2013) |
| " Here, we investigated the effect of SPL on blood glucose levels in SHR/NDmcr-cp(cp/cp) (ND) rats, an animal model of metabolic syndrome, in comparison with that of eplerenone (EPL), another MR antagonist." | 7.78 | Spironolactone, but not eplerenone, impairs glucose tolerance in a rat model of metabolic syndrome. ( Arai, K; Fujisawa, M; Homma, T; Ikeda, M; Ishii, M; Sada, T, 2012) |
| " It has been reported that eplerenone has a potential antihypertensive effect, with a profile slightly different from that of spironolactone, and has fewer adverse reactions, suggesting that it may become a first-line treatment for hypertension." | 7.76 | Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. ( Fukuda, S; Sato, A, 2010) |
| "Aldosterone was in the past considered only as a prohypertensinogenic agent." | 6.46 | Aldosterone in uremia - beyond blood pressure. ( Koleganova, N; Ritz, E, 2010) |
| "Features of visceral obesity and obstructive sleep apnea that may stimulate aldosterone secretion are described here." | 6.44 | Obesity, sleep apnea, aldosterone, and hypertension. ( Goodfriend, TL, 2008) |
| "Spironolactone treatment significantly decreased coronary TRPC expression and dysfunctions in MetS pigs." | 5.46 | Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs. ( Alloosh, M; Beli, E; Chakraborty, S; Chen, X; Grant, MB; Hiett, SC; Li, W; Long, X; Obukhov, AG; Riley, AM; Sturek, M; Temm, CJ; White, FA, 2017) |
| "Hypertension is often associated with metabolic syndrome (MetS), and serves as a risk factor of MetS and its complications." | 5.43 | Eplerenone restores 24-h blood pressure circadian rhythm and reduces advanced glycation end-products in rhesus macaques with spontaneous hypertensive metabolic syndrome. ( Ding, Y; Hou, N; Hu, X; Li, C; Liu, Y; Ma, D; Mao, J; Peng, Y; Shang, H; Sun, X; Wang, C; Wang, J; Xiao, RP; Xiao, Y; Zeng, F; Zhang, J; Zhang, X; Zhang, Y; Zheng, W, 2016) |
| "Proteinuria was prominent in SHR/NDmcr-cp compared with nonobese SHR, which was accompanied by podocyte injury as evidenced by foot process effacement, induction of desmin and attenuation of nephrin." | 5.33 | Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. ( Ando, K; Fujita, T; Gotoda, T; Nagase, M; Nagase, T; Shibata, S; Yoshida, S, 2006) |
| "To test this hypothesis, we conducted a balanced, randomized, double-blind, placebo-controlled, crossover study using selective MR blockade (eplerenone; 100 mg/day) for 1 month with 1 month washout in older adults with metabolic syndrome (62." | 5.20 | Effect of Selective Mineralocorticoid Receptor Blockade on Flow-Mediated Dilation and Insulin Resistance in Older Adults with Metabolic Syndrome. ( Christou, DD; English, M; Hwang, MH; Luttrell, M; Meade, TH; Yoo, JK, 2015) |
| "The purpose of this study was to identify the effects of spironolactone on left ventricular (LV) structure and function, and serological fibrosis markers in patients with metabolic syndrome (MS) taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers." | 5.15 | A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome. ( Kosmala, W; Marwick, TH; Mysiak, A; O'Moore-Sullivan, T; Przewlocka-Kosmala, M; Szczepanik-Osadnik, H, 2011) |
| "Aim of the study is to evaluate the impact of spironolactone (SPL) on indexes of metabolic syndrome (MS) and further investigate the mechanisms underlying its protective effects." | 3.79 | Spironolactone prevents dietary-induced metabolic syndrome by inhibiting PI3-K/Akt and p38MAPK signaling pathways. ( Liang, LY; Lin, YE; Liu, MJ; Long, HD; Zeng, ZH, 2013) |
| "Because the renin-angiotensin-aldosterone system has been implicated in the development of insulin resistance and promotion of fibrosis in some tissues, such as the vasculature, we examined the effect of eplerenone, a selective mineralocorticoid receptor (MR) antagonist, on nonalcoholic steatohepatitis (NASH) and metabolic phenotypes in a mouse model reflecting metabolic syndrome in humans." | 3.79 | Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet. ( Aruga, Y; Ishii, Y; Kanasaki, K; Kitada, M; Koya, D; Miyashita, Y; Nakamura, Y; Sasahara, M; Sasaki, M; Sasaoka, T; Shimano, H; Tsuneki, H; Wada, T, 2013) |
| " Here, we investigated the effect of SPL on blood glucose levels in SHR/NDmcr-cp(cp/cp) (ND) rats, an animal model of metabolic syndrome, in comparison with that of eplerenone (EPL), another MR antagonist." | 3.78 | Spironolactone, but not eplerenone, impairs glucose tolerance in a rat model of metabolic syndrome. ( Arai, K; Fujisawa, M; Homma, T; Ikeda, M; Ishii, M; Sada, T, 2012) |
| " It has been reported that eplerenone has a potential antihypertensive effect, with a profile slightly different from that of spironolactone, and has fewer adverse reactions, suggesting that it may become a first-line treatment for hypertension." | 3.76 | Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. ( Fukuda, S; Sato, A, 2010) |
| "Aldosterone was in the past considered only as a prohypertensinogenic agent." | 2.46 | Aldosterone in uremia - beyond blood pressure. ( Koleganova, N; Ritz, E, 2010) |
| "Features of visceral obesity and obstructive sleep apnea that may stimulate aldosterone secretion are described here." | 2.44 | Obesity, sleep apnea, aldosterone, and hypertension. ( Goodfriend, TL, 2008) |
| "Spironolactone treatment significantly decreased coronary TRPC expression and dysfunctions in MetS pigs." | 1.46 | Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs. ( Alloosh, M; Beli, E; Chakraborty, S; Chen, X; Grant, MB; Hiett, SC; Li, W; Long, X; Obukhov, AG; Riley, AM; Sturek, M; Temm, CJ; White, FA, 2017) |
| "Hypertension is often associated with metabolic syndrome (MetS), and serves as a risk factor of MetS and its complications." | 1.43 | Eplerenone restores 24-h blood pressure circadian rhythm and reduces advanced glycation end-products in rhesus macaques with spontaneous hypertensive metabolic syndrome. ( Ding, Y; Hou, N; Hu, X; Li, C; Liu, Y; Ma, D; Mao, J; Peng, Y; Shang, H; Sun, X; Wang, C; Wang, J; Xiao, RP; Xiao, Y; Zeng, F; Zhang, J; Zhang, X; Zhang, Y; Zheng, W, 2016) |
| "Metabolic syndrome is a major risk factor for the development of diabetes mellitus and cardiovascular diseases." | 1.42 | Adipocyte Mineralocorticoid Receptor Activation Leads to Metabolic Syndrome and Induction of Prostaglandin D2 Synthase. ( Adler, GK; Alvarez de la Rosa, D; El Mogrhabi, S; Fallo, F; Feraco, A; Jaisser, F; Nguyen Dinh Cat, A; Quilliot, D; Rossignol, P; Sierra-Ramos, C; Touyz, RM; Urbanet, R; Venteclef, N, 2015) |
| "Metabolic syndrome is a highly predisposing condition for cardiovascular disease and could be a cause of excess salt-induced organ damage." | 1.35 | Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder. ( Ando, K; Fujita, M; Fujita, T; Kawarazaki, H; Matsui, H; Nagae, A; Nagase, M; Shimosawa, T, 2008) |
| "Proteinuria was prominent in SHR/NDmcr-cp compared with nonobese SHR, which was accompanied by podocyte injury as evidenced by foot process effacement, induction of desmin and attenuation of nephrin." | 1.33 | Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. ( Ando, K; Fujita, T; Gotoda, T; Nagase, M; Nagase, T; Shibata, S; Yoshida, S, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (20.00) | 29.6817 |
| 2010's | 20 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, W | 1 |
| Chen, X | 1 |
| Riley, AM | 1 |
| Hiett, SC | 1 |
| Temm, CJ | 1 |
| Beli, E | 1 |
| Long, X | 1 |
| Chakraborty, S | 1 |
| Alloosh, M | 1 |
| White, FA | 1 |
| Grant, MB | 1 |
| Sturek, M | 1 |
| Obukhov, AG | 1 |
| Gamliel-Lazarovich, A | 1 |
| Raz-Pasteur, A | 1 |
| Coleman, R | 1 |
| Keidar, S | 1 |
| Long, HD | 1 |
| Lin, YE | 1 |
| Liu, MJ | 1 |
| Liang, LY | 1 |
| Zeng, ZH | 1 |
| Wada, T | 1 |
| Miyashita, Y | 1 |
| Sasaki, M | 1 |
| Aruga, Y | 1 |
| Nakamura, Y | 1 |
| Ishii, Y | 1 |
| Sasahara, M | 1 |
| Kanasaki, K | 1 |
| Kitada, M | 1 |
| Koya, D | 1 |
| Shimano, H | 1 |
| Tsuneki, H | 1 |
| Sasaoka, T | 1 |
| Urbanet, R | 1 |
| Nguyen Dinh Cat, A | 1 |
| Feraco, A | 1 |
| Venteclef, N | 1 |
| El Mogrhabi, S | 1 |
| Sierra-Ramos, C | 1 |
| Alvarez de la Rosa, D | 1 |
| Adler, GK | 2 |
| Quilliot, D | 1 |
| Rossignol, P | 1 |
| Fallo, F | 1 |
| Touyz, RM | 1 |
| Jaisser, F | 1 |
| Hwang, MH | 1 |
| Yoo, JK | 1 |
| Luttrell, M | 1 |
| Meade, TH | 1 |
| English, M | 1 |
| Christou, DD | 1 |
| Kanchan, V | 1 |
| Pawan, K | 1 |
| Sudhir, V | 1 |
| Harpreet Singh, K | 1 |
| Zhang, Y | 1 |
| Zheng, W | 1 |
| Liu, Y | 1 |
| Wang, J | 1 |
| Peng, Y | 1 |
| Shang, H | 1 |
| Hou, N | 1 |
| Hu, X | 1 |
| Ding, Y | 1 |
| Xiao, Y | 1 |
| Wang, C | 1 |
| Zeng, F | 1 |
| Mao, J | 1 |
| Zhang, J | 1 |
| Ma, D | 1 |
| Sun, X | 1 |
| Li, C | 1 |
| Xiao, RP | 1 |
| Zhang, X | 1 |
| Matsui, H | 2 |
| Ando, K | 2 |
| Kawarazaki, H | 1 |
| Nagae, A | 1 |
| Fujita, M | 1 |
| Shimosawa, T | 1 |
| Nagase, M | 4 |
| Fujita, T | 4 |
| Goodfriend, TL | 1 |
| Sato, A | 1 |
| Fukuda, S | 1 |
| Ritz, E | 1 |
| Koleganova, N | 1 |
| Tirosh, A | 1 |
| Garg, R | 1 |
| Costa, MB | 2 |
| Andrade Ezequiel, DG | 1 |
| Morais Lovis, JC | 1 |
| Oliveira, MM | 1 |
| Baumgratz de Paula, R | 1 |
| Polyzos, SA | 1 |
| Kountouras, J | 1 |
| Zavos, C | 1 |
| Deretzi, G | 1 |
| Leung, DY | 1 |
| Kosmala, W | 1 |
| Przewlocka-Kosmala, M | 1 |
| Szczepanik-Osadnik, H | 1 |
| Mysiak, A | 1 |
| O'Moore-Sullivan, T | 1 |
| Marwick, TH | 1 |
| Lovisi, JC | 1 |
| Ezequiel, DA | 1 |
| Bicalho, TC | 1 |
| Barros, FC | 1 |
| Souza, Gdo C | 1 |
| Paula, RB | 1 |
| Homma, T | 1 |
| Fujisawa, M | 1 |
| Arai, K | 1 |
| Ishii, M | 1 |
| Sada, T | 1 |
| Ikeda, M | 1 |
| Suzuki, H | 1 |
| Shuto, H | 1 |
| Shuto, C | 1 |
| Ohara, I | 1 |
| Inokuma, S | 1 |
| Abe, Y | 1 |
| Sukigara, M | 1 |
| Bonny, AE | 1 |
| Appelbaum, H | 1 |
| Connor, EL | 1 |
| Cromer, B | 1 |
| DiVasta, A | 1 |
| Gomez-Lobo, V | 1 |
| Harel, Z | 1 |
| Huppert, J | 1 |
| Sucato, G | 1 |
| Yoshida, S | 1 |
| Shibata, S | 2 |
| Nagase, T | 1 |
| Gotoda, T | 2 |
| Caprio, M | 1 |
| Fève, B | 1 |
| Claës, A | 1 |
| Viengchareun, S | 1 |
| Lombès, M | 1 |
| Zennaro, MC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Spironolactone and Vitamin E Versus Vitamin E on Serum Adipocytokines Levels in Patients With Biopsy-proven Nonalcoholic Fatty Liver Disease-A Phase II Study[NCT01147523] | Phase 2 | 30 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for spironolactone and Cardiometabolic Syndrome
| Article | Year |
|---|---|
Obesity, sleep apnea, aldosterone, and hypertension.
Topics: Aldosterone; Humans; Hypertension; Metabolic Syndrome; Mineralocorticoid Receptor Antagonists; Obesi | 2008 |
Aldosterone in uremia - beyond blood pressure.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosterone; Endothelial Cells; Endothelium, Vascular; | 2010 |
[Chronic kidney disease and the aldosterone/mineralocorticoid receptor system].
Topics: Aldosterone; Animals; Chronic Disease; Eplerenone; Humans; Kidney Diseases; Metabolic Syndrome; Mine | 2010 |
Mineralocorticoid receptor antagonists and the metabolic syndrome.
Topics: Aldosterone; Antihypertensive Agents; Eplerenone; Humans; Hypertension; Inflammation; Insulin Resist | 2010 |
4 trials available for spironolactone and Cardiometabolic Syndrome
| Article | Year |
|---|---|
Effect of Selective Mineralocorticoid Receptor Blockade on Flow-Mediated Dilation and Insulin Resistance in Older Adults with Metabolic Syndrome.
Topics: Aged; Brachial Artery; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Eplerenone; H | 2015 |
Effect of low-dose mineralocorticoid receptor antagonists on metabolic profile and endothelial dysfunction in metabolic syndrome.
Topics: Adult; Aged, 80 and over; Biomarkers; Eplerenone; Female; Humans; Lipids; Male; Metabolic Syndrome; | 2016 |
Aldosterone antagonist decreases blood pressure and improves metabolic parameters in obese patients with the metabolic syndrome.
Topics: Adult; Aged; Blood Pressure; Female; Humans; Hypertension; Male; Metabolic Syndrome; Middle Aged; Mi | 2010 |
A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.
Topics: Aged; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme I | 2011 |
17 other studies available for spironolactone and Cardiometabolic Syndrome
| Article | Year |
|---|---|
Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs.
Topics: Animals; Calcium Signaling; Cells, Cultured; Coronary Artery Disease; Coronary Vessels; Disease Mode | 2017 |
The effects of aldosterone on diet-induced fatty liver formation in male C57BL/6 mice: comparison of adrenalectomy and mineralocorticoid receptor blocker.
Topics: Adrenalectomy; Aldosterone; Animals; Blood Glucose; Blood Pressure; Cells, Cultured; Cholesterol; Di | 2013 |
Spironolactone prevents dietary-induced metabolic syndrome by inhibiting PI3-K/Akt and p38MAPK signaling pathways.
Topics: Aldosterone; Animals; Apoptosis; Diet, High-Fat; Dyslipidemias; Hypertension; Insulin-Secreting Cell | 2013 |
Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet.
Topics: Animals; Cells, Cultured; Diet, High-Fat; Dietary Carbohydrates; Eplerenone; Fatty Liver; Fructose; | 2013 |
Adipocyte Mineralocorticoid Receptor Activation Leads to Metabolic Syndrome and Induction of Prostaglandin D2 Synthase.
Topics: 3T3-L1 Cells; Adipocytes, White; Aldosterone; Animals; Cell Line, Tumor; Dibenzocycloheptenes; Enzym | 2015 |
Eplerenone restores 24-h blood pressure circadian rhythm and reduces advanced glycation end-products in rhesus macaques with spontaneous hypertensive metabolic syndrome.
Topics: Anesthesia, General; Animals; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Drug Evalua | 2016 |
Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder.
Topics: Aldosterone; Animals; Blood Pressure Determination; Disease Models, Animal; Echocardiography, Dopple | 2008 |
Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension.
Topics: Aged; Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; A | 2010 |
Spironolactone revisited.
Topics: Blood Pressure; Female; Humans; Hypertension; Male; Metabolic Syndrome; Mineralocorticoid Receptor A | 2011 |
Aldosterone blockade in metabolic syndrome: hitting the target or still missing some links?
Topics: Female; Humans; Hypertrophy, Left Ventricular; Male; Metabolic Syndrome; Mineralocorticoid Receptor | 2011 |
Espironolactone improves flow-mediated vasodilatation in subjects with the metabolic syndrome.
Topics: Adolescent; Adult; Endothelium, Vascular; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Min | 2011 |
Spironolactone, but not eplerenone, impairs glucose tolerance in a rat model of metabolic syndrome.
Topics: Animals; Area Under Curve; Blood Glucose; Eplerenone; Glucose; Glucose Intolerance; Metabolic Syndro | 2012 |
Eplerenone, an aldosterone blocker, is more effective in reducing blood pressure in patients with, than without, metabolic syndrome.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Eplerenone; Female; Humans; Male; Metabo | 2012 |
Clinical variability in approaches to polycystic ovary syndrome.
Topics: Adolescent; Contraceptives, Oral; Cross-Sectional Studies; Data Collection; Exercise; Feeding Behavi | 2012 |
Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors.
Topics: Adipocytes; Adrenal Glands; Aldosterone; Animals; Cyclic N-Oxides; Disease Models, Animal; Eplerenon | 2006 |
Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis.
Topics: Adipocytes, White; Adipogenesis; Adipose Tissue, White; Aldosterone; Animals; Cell Differentiation; | 2007 |
Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress.
Topics: Aldosterone; Animals; Antioxidants; Cyclic N-Oxides; Disease Models, Animal; Eplerenone; Hypertensio | 2007 |